Ceruloplasmin dysfunction and therapeutic potential for Parkinson disease

Basal Lipid Peroxidation in Substantia Nigra Is Increased in Parkinson's Disease

Dexter, D. T., Carter, C. J., Wells, F. R., Javoy-Agid, F., Agid, Y., Lees, A. J., Jenner, P. G., & MARSDEN, C. D. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb09133.x · Cited by 1,397

C ERULOPLASMIN M ETABOLISM AND F UNCTION

Hellman, N. E., & Gitlin, J. D. (2002) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.22.012502.114457 · Cited by 954

Iron-Export Ferroxidase Activity of β-Amyloid Precursor Protein Is Inhibited by Zinc in Alzheimer's Disease

Duce, J. A., Tsatsanis, A., Cater, M. A., James, S., Robb, E. L., Wikhe, K., Leong, S. L., Perez, K. A., Johanssen, T., Greenough, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.08.014 · Cited by 695

The possible significance of the ferrous oxidase activity of ceruloplasmin in normal human serum.

Osaki, S., Johnson, D. A., & Frieden, E. (1966) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)96527-0 · Cited by 679

Genetic or Pharmacological Iron Chelation Prevents MPTP-Induced Neurotoxicity In Vivo

Kaur, D., Yantiri, F., Rajagopalan, S., Kumar, J., Mo, J. Q., Boonplueang, R., Viswanath, V., Jacobs, R., Yang, L., Beal, M. F., et al. (2003) · Neuron · doi:10.1016/s0896-6273(03)00126-0 · Cited by 620

Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export

Lei, P., Ayton, S., Finkelstein, D. I., Spoerri, L., Ciccotosto, G. D., Wright, D. K., Wong, B. X. W., Adlard, P. A., Cherny, R. A., Lam, L. Q., et al. (2012) · Nature Medicine · doi:10.1038/nm.2613 · Cited by 594

The A53T α-Synuclein Mutation Increases Iron-Dependent Aggregation and Toxicity

Golts, N., Petrucelli, L., Hardy, J., Lee, J. M., Farer, M., & Wolozin, B. L. (2000) · Journal of Neuroscience · doi:10.1523/jneurosci.20-16-06048.2000 · Cited by 550

Ceruloplasmin regulates iron levels in the CNS and prevents free radical injury

Patel, B. N., Dunn, R. J., Jeong, S. Y., Zhu, Q., Julien, J.-P., & David, S. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-15-06578.2002 · Cited by 379

Individual dopaminergic neurons show raised iron levels in Parkinson disease

Oakley, A. E., Collingwood, J. F., Dobson, J., Love, G., Perrott, H. R., Edwardson, J. A., Elstner, M., & Morris, C. M. (2007) · Neurology · doi:10.1212/01.wnl.0000262033.01945.9a · Cited by 273

Sequestration of iron by Lewy bodies in Parkinson's disease

Castellani, R. J., Siedlak, S. L., Perry, G., & Smith, M. A. (2000) · Acta Neuropathologica · doi:10.1007/s004010050001 · Cited by 265

The role of iron in brain ageing and neurodegenerative disorders

Ward, R. J., Zucca, F. A., Duyn, J. H., Crichton, R. R., & Zecca, L. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70117-6 · Cited by 1,819

Wilson's disease and other neurological copper disorders

Bandmann, O., Weiss, K. H., & Kaler, S. G. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70190-5 · Cited by 1,067

Oxidative stress in the aging substantia nigra and the etiology of Parkinson's disease

Trist, B. G., Hare, D. J., & Double, K. L. (2019) · Aging Cell · doi:10.1111/acel.13031 · Cited by 778

Tau-mediated iron export prevents ferroptotic damage after ischemic stroke

Tuo, Q.-Z., Lei, P., Jackman, K. A., Li, X.-L., Xiong, H., Li, X.-L., Liuyang, Z.-Y., Roisman, L. C., Zhang, S.-T., Ayton, S., et al. (2017) · Molecular Psychiatry · doi:10.1038/mp.2017.171 · Cited by 715

Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson's disease

Zucca, F. A., Segura-Aguilar, J., Ferrari, E., Muñoz, P., Paris, I., Sulzer, D., Sarna, T., Casella, L., & Zecca, L. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.09.012 · Cited by 659

Manganese Is Essential for Neuronal Health

Horning, K. J., Caito, S. W., Tipps, K. G., Bowman, A. B., & Aschner, M. (2015) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-071714-034419 · Cited by 623

Iron neurochemistry in Alzheimer's disease and Parkinson's disease: targets for therapeutics

Belaidi, A. A., & Bush, A. I. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13425 · Cited by 594

Ferroptosis and its potential role in the physiopathology of Parkinson’s Disease

Mahoney‐Sanchez, L., Bouchaoui, H., Ayton, S., Devos, D., Duce, J. A., & Devedjian, J.-C. (2020) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2020.101890 · Cited by 572

Iron homeostasis and iron-regulated ROS in cell death, senescence and human diseases

Nakamura, T., Naguro, I., & Ichijo, H. (2019) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2019.06.010 · Cited by 529

Biological metals and metal-targeting compounds in major neurodegenerative diseases

Barnham, K. J., & Bush, A. I. (2014) · Chem. Soc. Rev. · doi:10.1039/c4cs00138a · Cited by 497

Striking while the iron is hot: Iron metabolism and ferroptosis in neurodegeneration

Masaldan, S., Bush, A. I., Devos, D., Rolland, A., & Moreau, C. (2018) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2018.09.033 · Cited by 494

Signaling pathways in Parkinson’s disease: molecular mechanisms and therapeutic interventions

Xu, D.-C., Yong, C., Xu, Y., Chen-Yu, S., & Peng, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01353-3 · Cited by 528

Ferroptosis and Its Role in Diverse Brain Diseases

Weiland, A., Wang, Y., Wu, W., Lan, X., Han, X., Li, Q., & Wang, J. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1403-3 · Cited by 473

A delicate balance: Iron metabolism and diseases of the brain

Hare, D. J., Ayton, S., Bush, A. I., & Lei, P. (2013) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2013.00034 · Cited by 459

Molecular mechanisms of ferroptosis and their involvement in brain diseases

Costa, I., Barbosa, D. J., Benfeito, S., Silva, V., Chavarria, D., Borges, F., Remião, F., & Silva, R. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108373 · Cited by 402

Ferroptosis and cell death mechanisms in Parkinson's disease

Guiney, S. J., Adlard, P. A., Bush, A. I., Finkelstein, D. I., & Ayton, S. (2017) · Neurochemistry International · doi:10.1016/j.neuint.2017.01.004 · Cited by 353

Ferroptosis in Parkinson’s disease: glia–neuron crosstalk

Wang, Z.-L., Yuan, L., Li, W., & Li, J.-Y. (2022) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2022.02.003 · Cited by 319

Selenium, selenoproteins and neurodegenerative diseases

Cardoso, B. R., Roberts, B. R., Bush, A. I., & Hare, D. J. (2015) · Metallomics · doi:10.1039/c5mt00075k · Cited by 300

Iron and dopamine: a toxic couple

Hare, D. J., & Double, K. L. (2016) · Brain · doi:10.1093/brain/aww022 · Cited by 291

Glutathione peroxidase 4: a new player in neurodegeneration?

Cardoso, B. R., Hare, D. J., Bush, A. I., & Roberts, B. R. (2016) · Molecular Psychiatry · doi:10.1038/mp.2016.196 · Cited by 287

Ferroptosis and Its Potential Role in Human Diseases

Han, C., Liu, Y., Dai, R., Ismail, N., Su, W., & Li, B. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00239 · Cited by 283

NRF2, a Superstar of Ferroptosis

Yan, R., Lin, B., Jin, W., Tang, L., Hu, S., & Cai, R. (2023) · Antioxidants · doi:10.3390/antiox12091739 · Cited by 292

Homeostasis and metabolism of iron and other metal ions in neurodegenerative diseases

Chen, L., Shen, Q., Liu, Y., Zhang, Y., Sun, L., Ma, X., Song, N., & Xie, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02071-0 · Cited by 279

The neurotoxicity of iron, copper and manganese in Parkinson's and Wilson's diseases

Dušek, P., Roos, P. M., Litwin, T., Schneider, S. A., Flaten, T. P., & Aaseth, J. (2014) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2014.05.007 · Cited by 260

Copper pathology in vulnerable brain regions in Parkinson's disease

Davies, K. M., Bohic, S., Carmona, A., Ortega, R., Cottam, V., Hare, D. J., Finberg, J. P. M., Reyes, S., Halliday, G. M., Mercer, J. F. B., et al. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.09.034 · Cited by 244

Copper Ions and Parkinson’s Disease: Why Is Homeostasis So Relevant?

Bisaglia, M., & Bubacco, L. (2020) · Biomolecules · doi:10.3390/biom10020195 · Cited by 226

Physical activity and the brain: A review of this dynamic, bi-directional relationship

Loprinzi, P. D., Herod, S. M., Cardinal, B. J., & Noakes, T. D. (2013) · Brain Research · doi:10.1016/j.brainres.2013.10.004 · Cited by 234

The mechanism of ferroptosis and its related diseases

Feng, S., Tang, D., Wang, Y., Li, X., Bao, H., Tang, C., Dong, X., Li, X., Yang, Q., Yan, Y., et al. (2023) · Molecular Biomedicine · doi:10.1186/s43556-023-00142-2 · Cited by 241

Region‐specific disturbed iron distribution in early idiopathic P arkinson's disease measured by quantitative susceptibility mapping

He, N., Ling, H., Ding, B., Huang, J., Zhang, Y., Zhang, Z., Liu, C., Chen, K., & Yan, F. (2015) · Human Brain Mapping · doi:10.1002/hbm.22928 · Cited by 222

Ferroptosis as a mechanism of neurodegeneration in Alzheimer's disease

Jakaria, M., Belaidi, A. A., Bush, A. I., & Ayton, S. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15519 · Cited by 212

Copper and Copper Proteins in Parkinson’s Disease

Montes, S., Rivera-Mancia, S., Diaz-Ruiz, A., Tristan-Lopez, L., & Rios, C. (2014) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2014/147251 · Cited by 203

Ferroptosis promotes T-cell activation-induced neurodegeneration in multiple sclerosis

Luoqian, J., Yang, W., Ding, X., Tuo, Q., Xiang, Z., Zheng, Z., Guo, Y., Li, L., Guan, P., Ayton, S., et al. (2022) · Cellular and Molecular Immunology · doi:10.1038/s41423-022-00883-0 · Cited by 189

Brain Iron Metabolism Dysfunction in Parkinson’s Disease

Jiang, H. F., Wang, J., Rogers, J. T., & Xie, J. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-9879-1 · Cited by 188

Iron Accumulates in Huntington’s Disease Neurons: Protection by Deferoxamine

Chen, J., Marks, E. S., Lai, B. C. H., Zhang, Z., Duce, J. A., Lam, L. Q., Volitakis, I., Bush, A. I., Hersch, S. M., & Fox, J. H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077023 · Cited by 176

Nigral Iron Elevation Is an Invariable Feature of Parkinson’s Disease and Is a Sufficient Cause of Neurodegeneration

Ayton, S., & Lei, P. (2014) · BioMed Research International · doi:10.1155/2014/581256 · Cited by 163

Iron, ferroptosis, and ischemic stroke

Guo, J., Tuo, Q., & Lei, P. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.15807 · Cited by 163

The Aging of Iron Man

Ashraf, A., Clark, M., & So, P. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00065 · Cited by 163

Why should neuroscientists worry about iron? The emerging role of ferroptosis in the pathophysiology of neuroprogressive diseases

Morris, G., Berk, M., Carvalho, A. F., Maes, M. H. J., Walker, A. J., & Puri, B. K. (2017) · Behavioural Brain Research · doi:10.1016/j.bbr.2017.12.036 · Cited by 155

Metals and Alzheimer’s Disease: How Far Have We Come in the Clinic?

Adlard, P. A., & Bush, A. I. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170662 · Cited by 155

The molecular and cellular basis of copper dysregulation and its relationship with human pathologies

Maung, M. T., Carlson, A., Olea‐Flores, M., Elkhadragy, L., Schachtschneider, K. M., Navarro‐Tito, N., & Padilla‐Benavides, T. (2021) · The FASEB Journal · doi:10.1096/fj.202100273rr · Cited by 158

β-Amyloid Precursor Protein Does Not Possess Ferroxidase Activity but Does Stabilize the Cell Surface Ferrous Iron Exporter Ferroportin

Wong, B. X. W., Tsatsanis, A., Lim, L. Q., Adlard, P. A., Bush, A. I., & Duce, J. A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0114174 · Cited by 155

Motor and cognitive deficits in aged tau knockout mice in two background strains

Lei, P., Ayton, S., Moon, S., Zhang, Q., Volitakis, I., Finkelstein, D. I., & Bush, A. I. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-29 · Cited by 145

Redox Mechanisms in Neurodegeneration: From Disease Outcomes to Therapeutic Opportunities

Sbodio, J. I., Snyder, S. H., & Paul, B. D. (2018) · Antioxidants and Redox Signaling · doi:10.1089/ars.2017.7321 · Cited by 149

Superoxide dismutase and neurological disorders

Chidambaram, S. B., Anand, N., Varma, S. R., Ramamurthy, S., Vichitra, C., Sharma, A., Mahalakshmi, A. M., & Essa, M. M. (2024) · IBRO Neuroscience Reports · doi:10.1016/j.ibneur.2023.11.007 · Cited by 162

Copper dyshomoeostasis in Parkinson's disease: implications for pathogenesis and indications for novel therapeutics

Davies, K. M., Mercer, J. F. B., Chen, N., & Double, K. L. (2016) · Clinical Science · doi:10.1042/cs20150153 · Cited by 139

Parkinson's Disease Iron Deposition Caused by Nitric Oxide-Induced Loss of β-Amyloid Precursor Protein

Ayton, S., Lei, P., Hare, D. J., Duce, J. A., George, J. L., Adlard, P. A., McLean, C., Rogers, J. T., Cherny, R. A., Finkelstein, D. I., et al. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.3439-14.2015 · Cited by 131

Biometals and Their Therapeutic Implications in Alzheimer's Disease

Ayton, S., Lei, P., & Bush, A. I. (2014) · Neurotherapeutics · doi:10.1007/s13311-014-0312-z · Cited by 134

The role of copper ions in pathophysiology and fluorescent sensors for the detection thereof

Verwilst, P., Sunwoo, K., & Kim, J. S. (2015) · Chemical Communications · doi:10.1039/c4cc10366a · Cited by 133

Dysregulation of Iron Homeostasis in the Central Nervous System and the Role of Ferroptosis in Neurodegenerative Disorders

David, S., Jhelum, P., Ryan, F., Jeong, S. Y., & Kroner, A. (2021) · Antioxidants and Redox Signaling · doi:10.1089/ars.2021.0218 · Cited by 134

Iron as a therapeutic target for Parkinson's disease

Moreau, C., Duce, J. A., Rascol, O., Devedjian, J.-C., Berg, D., Dexter, D. T., Cabantchik, Z. I., Bush, A. I., Devos, D., & the FAIRPARK‐II study group (2018) · Movement Disorders · doi:10.1002/mds.27275 · Cited by 127

Conservative iron chelation for neurodegenerative diseases such as Parkinson’s disease and amyotrophic lateral sclerosis

studygroups, T. F.-I. A. F.-I., Devos, D., Cabantchik, Z. I., Moreau, C., Danel-Brunaud, V., Mahoney‐Sanchez, L., Bouchaoui, H., Gouel, F., Rolland, A., Duce, J. A., et al. (2020) · Journal of Neural Transmission · doi:10.1007/s00702-019-02138-1 · Cited by 135

Subcellular compartmentalisation of copper, iron, manganese, and zinc in the Parkinson's disease brain

Genoud, S., Roberts, B. R., Gunn, A. P., Halliday, G. M., Lewis, S. J. G., Ball, H. J., Hare, D. J., & Double, K. L. (2017) · Metallomics · doi:10.1039/c7mt00244k · Cited by 126

Iron supplementation and iron-fortified foods: a review

Man, Y., Xu, T., Adhikari, B., Zhou, C., Wang, Y., & Wang, B. (2021) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2021.1876623 · Cited by 139

Neurotoxicity of Copper

Bulcke, F., Dringen, R., & Scheiber, I. F. (2017) · Advances in neurobiology · doi:10.1007/978-3-319-60189-2_16 · Cited by 117

Role of iron in neurodegenerative diseases

Li, K., & Reichmann, H. (2016) · Journal of Neural Transmission · doi:10.1007/s00702-016-1508-7 · Cited by 121

Abnormal Copper Homeostasis: Mechanisms and Roles in Neurodegeneration

Manto, M. U. (2014) · Toxics · doi:10.3390/toxics2020327 · Cited by 118

Mitochondrial iron metabolism and neurodegenerative diseases

Cheng, R., Dhorajia, V. V., Kim, J., & Kim, Y. (2021) · NeuroToxicology · doi:10.1016/j.neuro.2021.11.003 · Cited by 121

Connexin 30 deficiency attenuates A2 astrocyte responses and induces severe neurodegeneration in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride Parkinson’s disease animal model

Fujita, A., Yamaguchi, H., Yamasaki, R., Cui, Y., Matsuoka, Y., Yamada, K., & Kira, J. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1251-0 · Cited by 118

Ferroptosis and Its Multifaceted Roles in Cerebral Stroke

Zhang, Y., Lu, X., Tai, B., Li, W., & Li, T. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.615372 · Cited by 109

Iron and Neurodegeneration: Is Ferritinophagy the Link?

Biasiotto, G., Lorenzo, D. D., Archetti, S., & Zanella, I. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9473-y · Cited by 105

ACSL4 and the lipoxygenases 15/15B are pivotal for ferroptosis induced by iron and PUFA dyshomeostasis in dopaminergic neurons

Bouchaoui, H., Mahoney‐Sanchez, L., Garçon, G., Berdeaux, O., Alleman, L., Devos, D., Duce, J. A., & Devedjian, J.-C. (2022) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2022.12.086 · Cited by 112

The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson’s disease

Finkelstein, D. I., Billings, J. L., Adlard, P. A., Ayton, S., Sedjahtera, A., Masters, C. L., Wilkins, S., Shackleford, D. M., Charman, S. A., Bal, W., et al. (2017) · Acta Neuropathologica Communications · doi:10.1186/s40478-017-0456-2 · Cited by 104

Ceruloplasmin activity and iron chelation treatment of patients with Parkinson’s disease

Grolez, G., Moreau, C., Sablonnière, B., Garçon, G., Devedjian, J.-C., Meguig, S., Gelé, P., Delmaire, C., Bordet, R., Defebvre, L., et al. (2015) · BMC Neurology · doi:10.1186/s12883-015-0331-3 · Cited by 101

Is early-life iron exposure critical in neurodegeneration?

Hare, D. J., Arora, M., Jenkins, N. L., Finkelstein, D. I., Doble, P., & Bush, A. I. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.100 · Cited by 100

Does Ceruloplasmin Defend Against Neurodegenerative Diseases?

Wang, B., & Wang, X. (2018) · Current Neuropharmacology · doi:10.2174/1570159x16666180508113025 · Cited by 104

Treating Alzheimer's disease by targeting iron

Nikseresht, S., Bush, A. I., & Ayton, S. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14567 · Cited by 98

Deferiprone in Alzheimer Disease

Ayton, S., Barton, D., Brew, B. J., Brodtmann, A. G., Clarnette, R., Desmond, P. M., Devos, D., Ellis, K. A., Fazlollahi, A., Fradette, C., et al. (2024) · JAMA Neurology · doi:10.1001/jamaneurol.2024.3733 · Cited by 97

The Latest View on the Mechanism of Ferroptosis and Its Research Progress in Spinal Cord Injury

Chen, Y., Liu, S., Li, J., Li, Z., Quan, J., Liu, X., Tang, Y., & Liu, B. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/6375938 · Cited by 100

Molecular changes in the postmortem parkinsonian brain

Toulorge, D., Schapira, A. H. V., & Hajj, R. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13696 · Cited by 95

Mangiferin: A multipotent natural product preventing neurodegeneration in Alzheimer’s and Parkinson’s disease models

Feng, S.-T., Wang, Z.-Z., Yuan, Y.-H., Sun, H.-M., Chen, N.-H., & Zhang, Y. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104336 · Cited by 96

Brain iron accumulation exacerbates the pathogenesis of MPTP-induced Parkinson’s disease

You, L., Li, F., Wang, L., Zhao, S., Wang, S.-M., Zhang, L.-L., Zhang, L.-H., Duan, X.-L., Yu, P., & Chang, Y. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.09.071 · Cited by 92

Brain Iron Metabolism, Redox Balance and Neurological Diseases

Gao, G., You, L., Zhang, J. J., Chang, Y., & Yu, P. (2023) · Antioxidants · doi:10.3390/antiox12061289 · Cited by 95

Clioquinol rescues Parkinsonism and dementia phenotypes of the tau knockout mouse

Lei, P., Ayton, S., Appukuttan, A. T., Volitakis, I., Adlard, P. A., Finkelstein, D. I., & Bush, A. I. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.03.015 · Cited by 89

Ferroptosis: An emerging therapeutic target in stroke

Liu, Y., Fang, Y., Zhang, Z., Luo, Y., Zhang, A., Lenahan, C., & Chen, S. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15351 · Cited by 84

Iron accumulation confers neurotoxicity to a vulnerable population of nigral neurons: implications for Parkinson’s disease

Ayton, S., Lei, P., Adlard, P. A., Volitakis, I., Cherny, R. A., Bush, A. I., & Finkelstein, D. I. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-27 · Cited by 79

Post translational changes to α-synuclein control iron and dopamine trafficking; a concept for neuron vulnerability in Parkinson’s disease

Duce, J. A., Wong, B. X. W., Durham, H., Devedjian, J.-C., Smith, D. P., & Devos, D. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0186-8 · Cited by 81

Therapeutic Insights on Ferroptosis in Parkinson's disease

Thapa, K., Khan, H., Kanojia, N., Singh, T. G., Kaur, A., & Kaur, G. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175133 · Cited by 76

The biology of mammalian multi-copper ferroxidases

Helman, S. L., Zhou, J., Fuqua, B. K., Lu, Y., Collins, J. F., Chen, H., Vulpe, C. D., Anderson, G. J., & Frazer, D. M. (2022) · BioMetals · doi:10.1007/s10534-022-00370-z · Cited by 83

Targeting the Labile Iron Pool with Engineered DFO Nanosheets to Inhibit Ferroptosis for Parkinson's Disease Therapy

Li, L., Yuan, J., Dai, Z., Song, X., Tu, Q., Cui, X., Zhai, S., Chen, X., He, Z., Fang, B., et al. (2024) · Advanced Materials · doi:10.1002/adma.202409329 · Cited by 86

Crosstalk between Nrf2 signaling and mitochondrial function in Parkinson's disease

Kaidery, N. A., Ahuja, M., & Thomas, B. (2019) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2019.103413 · Cited by 75

Visualising mouse neuroanatomy and function by metal distribution using laser ablation-inductively coupled plasma-mass spectrometry imaging

Paul, B. T., Hare, D. J., Bishop, D., Paton, C., Nguyen, V. T., Cole, N., Niedwiecki, M. M., Andreozzi, E. M., Vais, A., Billings, J. L., et al. (2015) · Chemical Science · doi:10.1039/c5sc02231b · Cited by 75

Ferroptosis: A potential therapeutic target for neurodegenerative diseases

Vitalakumar, D., Sharma, A., & Flora, S. J. S. (2021) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.22830 · Cited by 75

Microglial ferroptotic stress causes non-cell autonomous neuronal death

Liddell, J. R., Hilton, J. B. W., Kysenius, K., Nikseresht, S., McInnes, L. E., Hare, D. J., Paul, B. T., Trist, B. G., Double, K. L., Mercer, S. W., et al. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00691-8 · Cited by 77

Neuroimaging of Parkinson's disease by quantitative susceptibility mapping

Guan, X., Lancione, M., Ayton, S., Dušek, P., Langkammer, C., & Zhang, M. (2024) · NeuroImage · doi:10.1016/j.neuroimage.2024.120547 · Cited by 73

Metal Chelation Therapy and Parkinson’s Disease: A Critical Review on the Thermodynamics of Complex Formation between Relevant Metal Ions and Promising or Established Drugs

Tosato, M., & Marco, V. D. (2019) · Biomolecules · doi:10.3390/biom9070269 · Cited by 71

Overexpression of alpha-synuclein at non-toxic levels increases dopaminergic cell death induced by copper exposure via modulation of protein degradation pathways

Anandhan, A., Rodríguez‐Rocha, H., Bohovych, I., Griggs, A. M., Zavala-Flores, L. M., Reyes‐Reyes, E. M., Seravalli, J., Stanciu, L., Lee, J., Rochet, J., et al. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.11.018 · Cited by 73

Iron Chelation Nanoparticles with Delayed Saturation as an Effective Therapy for Parkinson Disease

Wang, N., Jin, X., Guo, D., Tong, G., & Zhu, X. (2016) · Biomacromolecules · doi:10.1021/acs.biomac.6b01547 · Cited by 71

Decreased Plasma Iron in Alzheimer’s Disease Is Due to Transferrin Desaturation

Hare, D. J., Doecke, J. D., Faux, N. G., Rembach, A., Volitakis, I., Fowler, C. J., Grimm, R., Doble, P., Cherny, R. A., Masters, C. L., et al. (2015) · ACS Chemical Neuroscience · doi:10.1021/cn5003557 · Cited by 70

Neuroferroptosis in health and diseases

Lei, P., Walker, T. L., & Ayton, S. (2025) · Nature reviews. Neuroscience · doi:10.1038/s41583-025-00930-5 · Cited by 77

Is copper a new target to counteract the progression of chronic diseases?

Balsano, C., Porcu, C., & Sideri, S. (2018) · Metallomics · doi:10.1039/c8mt00219c · Cited by 67

"Metal elements and pesticides as risk factors for Parkinson's disease - A review"

Ullah, I., Zhao, L., Yang, H. T., Muhammad, F., Alwayli, D., Wang, X., & Li, H. (2021) · Toxicology Reports · doi:10.1016/j.toxrep.2021.03.009 · Cited by 72

Nexus between mitochondrial function, iron, copper and glutathione in Parkinson's disease

Liddell, J. R., & White, A. R. (2017) · Neurochemistry International · doi:10.1016/j.neuint.2017.05.016 · Cited by 64

A brief history of brain iron accumulation in Parkinson disease and related disorders

Foley, P. B., Hare, D. J., & Double, K. L. (2022) · Journal of Neural Transmission · doi:10.1007/s00702-022-02505-5 · Cited by 61

Coordination and redox properties of copper interaction with α-synuclein

Valensin, D., Dell’Acqua, S., Kozłowski, H., & Casella, L. (2016) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2016.04.012 · Cited by 61

Brain iron concentrations in regions of interest and relation with serum iron levels in Parkinson disease

Costa‐Mallen, P., Gatenby, C., Friend, S., Maravilla, K. R., Hu, S., Cain, K. C., Agarwal, P., & Anzai, Y. (2017) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2017.04.035 · Cited by 62

Aceruloplasminemia: Waiting for an Efficient Therapy

Piperno, A., & Alessio, M. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00903 · Cited by 59

Ceruloplasmin and β-amyloid precursor protein confer neuroprotection in traumatic brain injury and lower neuronal iron

Ayton, S., Zhang, M., Roberts, B. R., Lam, L. Q., Lind, M., McLean, C., Bush, A. I., Frugier, T., Crack, P. J., & Duce, J. A. (2014) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2014.01.041 · Cited by 56

Increased metal content in the TDP-43A315T transgenic mouse model of frontotemporal lobar degeneration and amyotrophic lateral sclerosis

Dang, T. N. T., Lim, N. K.-H., Grubman, A., Li, Q., Volitakis, I., White, A. R., & Crouch, P. J. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00015 · Cited by 57

Metal Dyshomeostasis and Their Pathological Role in Prion and Prion-Like Diseases: The Basis for a Nutritional Approach

Toni, M., Massimino, M. L., Mario, A. D., Angiulli, E., & Spisni, E. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00003 · Cited by 56

Metal concentrations and distributions in the human olfactory bulb in Parkinson’s disease

Gardner, B., Dieriks, B. V., Cameron, S., Mendis, L. H. S., Turner, C. P., Faull, R. L. M., & Curtis, M. A. (2017) · Scientific Reports · doi:10.1038/s41598-017-10659-6 · Cited by 57

Functional relevance of ceruloplasmin mutations in Parkinson's Disease

Hochstrasser, H., Tomiuk, J., Walter, U., Behnke, S., Spiegel, J., Krüger, R., Becker, G., Riess, O., & Berg, D. (2005) · The FASEB Journal · doi:10.1096/fj.04-3486fje · Cited by 87

Ceruloplasmin activity and iron chelation treatment of patients with Parkinson’s disease

Grolez, G., Moreau, C., Sablonnière, B., Garçon, G., Devedjian, J.-C., Meguig, S., Gelé, P., Delmaire, C., Bordet, R., Defebvre, L., et al. (2015) · BMC Neurology · doi:10.1186/s12883-015-0331-3 · Cited by 101

Ceruloplasmin regulates iron levels in the CNS and prevents free radical injury

Patel, B. N., Dunn, R. J., Jeong, S. Y., Zhu, Q., Julien, J.-P., & David, S. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-15-06578.2002 · Cited by 379

Ceruloplasmin functional changes in Parkinson’s disease-cerebrospinal fluid

Barbariga, M., Curnis, F., Andolfo, A., Zanardi, A., Lazzaro, M., Conti, A., Magnani, G., Volonté, M. A., Ferrari, L. D., Comı, G., et al. (2015) · Molecular Neurodegeneration · doi:10.1186/s13024-015-0055-2 · Cited by 47

Ceruloplasmin oxidation, a feature of Parkinson's disease CSF, inhibits ferroxidase activity and promotes cellular iron retention

Olivieri, S., Conti, A., Iannaccone, S., Cannistraci, C. V., Campanella, A., Barbariga, M., Codazzi, F., Pelizzoni, I., Magnani, G., Pesca, M., et al. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.3768-11.2011 · Cited by 125